Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 6/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.49 |
| ▸ | RXRB | P28702 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RARA | P10276 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357478 | 0.97 | PLAU (0.55) | PTGESALOX5BCL2RARBEPHX2 | |
| SCHEMBL2349393 | 0.92 | PTGES (0.58) | PTGESALOX5BCL2RARBEPHX2 | |
| SCHEMBL2354635 | 0.89 | PLAU (0.53) | PTGESALOX5BCL2RARBNR1H4 | |
| SCHEMBL12243167 | 0.88 | MAPT (0.59) | PTGESALOX5PLAUALDH1A1MAPT | |
| SCHEMBL7607957 | 0.87 | RARB (0.65) | BCL2RARBEPHX2NR1H4EGFR | |
| SCHEMBL12243162 | 0.85 | MAPT (0.54) | BCL2PLAUALDH1A1MAPTKMT2A | |
| SCHEMBL2355299 | 0.84 | EGFR (0.57) | PLAUEGFRALDH1A1MAPTFFAR4 | |
| SCHEMBL2355298 | 0.82 | RARB (0.54) | PTGESALOX5RARBRXRARXRB | |
| SCHEMBL9939720 | 0.82 | RARB (0.51) | PTGESALOX5BCL2RARBRXRA | |
| SCHEMBL2353162 | 0.81 | EGFR (0.53) | PLAUEGFRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | PTGES 612/4885ALOX5 198/4885BCL2 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.